Large cell lymphomas and Hodgkin disease may develop during the course of chronic lymphocytic leukemia (CLL). In some cases the transformed cells are Epstein-Barr virus (EBV)–positive and not clonally related to the CLL cells. In other cases the transformed cells have the same clonal rearrangements as the CLL cells. Here we describe a composite lymphoma in a patient with CLL that exhibits a combination of CLL/small lymphocytic lymphoma, large cell lymphoma with anaplastic morphology, and Hodgkin lymphoma (HL).

### Introduction

In rare cases, high-grade B-cell lymphoma occurs in the setting of B-cell chronic lymphocytic leukemia (CLL). These lymphomas consist of monomorphic large B cells and are classified as large-cell B-cell non-Hodgkin lymphoma. In a small number of cases the transformation occurs to a component with characteristics of Hodgkin lymphoma (HL) and exhibits the typical Reed-Sternberg transformation. In a small number of cases the transformed cells have the same clonal rearrangements as the CLL cells. Here we describe a composite lymphoma in a patient with CLL that exhibits a combination of CLL/small lymphocytic lymphoma, large cell lymphoma with anaplastic morphology, and Hodgkin lymphoma (HL).

Although the large cell lymphoma cells are CD45RO and TIA-1–positive, suggesting a T- or 0-cell anaplastic large cell lymphoma (ALCL), the genetic analysis demonstrates immunoglobulin heavy chain (IgH) gene rearrangements for both alleles, carrying the same somatic mutations as observed in the CLL component. The Reed-Sternberg (R-S) cells in the Hodgkin component also strongly express TIA-1 but differ from the anaplastic large cells by the expression of CD15 and TARC and the presence of a prominent lymphocytic infiltrate. The ALCL and HL components both are EBV negative. Analysis of the IgH gene rearrangements in micromanipulated R-S cells revealed identical Ig gene rearrangements carrying the same somatic mutations as the CLL and the large cell components. The findings indicate transformation of the CLL cells into a large cell lymphoma with anaplastic morphology and a Hodgkin component.

© 2002 by The American Society of Hematology

### Patient, materials, and methods

#### Patient

A 76-year-old male, 4 years earlier diagnosed with CLL, presented with rapidly enlarging generalized lymphadenopathy. Histologic examination of a lymph node biopsy revealed a composite lymphoma. Approval for this study was obtained from the University Hospital Groningen institutional review board.

From the Department of Pathology and Laboratory Medicine, University and University Hospital Groningen, Groningen, The Netherlands.

Submitted November 16, 2001; accepted April 3, 2002.

Supported by a research grant from the Fondation Bekales (Bruxelles, Belgium).

Reprints: Sibrand Poppema, University Hospital Groningen, Department of Pathology and Laboratory Medicine, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands; e-mail: s.poppema@med.rug.nl.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

### DNA isolation and enrichment of tumor cells

DNA was isolated from 2 subsequent paraffin or frozen tissue sections including all 3 components with DEXPAT (Takara Shuzo, Otsu, Japan). Enrichment of lymphoma cells and DNA isolation were performed as described previously. Hematoxylin-eosin–stained sections were used for the isolation of CLL and ALCL cells, and CD15 staining was used to isolate R-S cells. About 100 lymphoma cells were microdissected in duplicate for the CLL and ALCL components. For the HL component, 10-20 cells were collected in duplicate.

### Amplification of the IgH gene rearrangement

### VDJ-PCR

VDJ rearrangements were amplified with a set of 6 VH family–specific primers and 2 different JH primers (J-1st 5'-cctgagagacggctgcc-3' and J-2nd 5'-ggagacggctgccggtt-3') in a semi-nested polymerase chain reaction (PCR). The preamplification step was carried out in 50 μL, containing 0.2 mM dNTP (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), 50 nM each VH-specific primer, 300 nM J-1st primer, 1.0 unit Taq-polymerase, and the PCR buffer provided by the manufacturer (Amersham Pharmacia Biotech). MgCl2 was added to a final concentration of 3.0 mM. The PCR program consisted of 30 cycles (1 minute at 94°C, 1 minute at 61°C, and 30 seconds at 72°C), followed by a final extension at 72°C for 10 minutes.

From www.bloodjournal.org by guest on July 9, 2017. For personal use only.
seconds at 72°C). The first denaturation step lasted for 5 minutes, and the final elongation step lasted for 7 minutes (GeneAmp 9700, Perkin Elmer Applied Biosystems, Foster City, CA). The postamplification (25 cycles) was performed with 1.0 μL PCR product using all separate VH primers (300 nM) and the J-2nd primer. MgCl₂ was added to a final concentration of 3.0 mM. The PCR program consisted of 30 cycles (1 minute at 94°C, 1 minute at 63°C, and 90 seconds at 72°C). An aliquot of 10 μL was analyzed for positive samples, a fragment of about 350 base pair (bp) was generated.

**FRII PCR.** The preamplification reaction was carried out as described for the VDJ-PCR. The postamplification was performed with 1.0 μL PCR product, 0.2 mM dNTPs, 1 unit Taq-polymerase, reaction buffer, 1 μM FR2A primer (5’-tgg < ag > tccg < ac > cag < cg > c < ct > < ct > cngg-3’), and 1 μM J-1st primer. MgCl₂ was added to a final concentration of 3.0 mM. The PCR program consisted of 30 cycles (1 minute at 94°C, 1 minute at 63°C, and 90 seconds at 72°C). An aliquot of 10 μL was analyzed.
on a 1.5% agarose gel. In positive samples a fragment of about 250 bp was generated. **FRIII PCR.** Amplification of the CDRIII region and interpretation of the results were carried out as described previously.\(^2,15\)

### Subcloning and sequence analysis

VDJ-PCR products of the expected size (~350 bp) were subcloned using the TA-cloning kit and the protocol provided by the manufacturer (Invitrogen, Groningen, The Netherlands). Seven to ten independent clones were sequenced on a MegaBace fluorescence sequencer and a dye Terminator Sequence Kit (both from Amersham Biosciences, Piscataway, NJ). Sequences were compared to the human germ line VH library (VBASE, http://www.mrc-cpe.cam.ac.uk/imt-doc/restricteddk.html). The DNAsis software (Molecular Biology Insights, Cascade, CO) was used for translation of the sequences. The framework regions (FR) and complement determining regions (CDR) were determined according to Kabat (http://immuno.bme.nwu.edu).\(^16\)

## Results

Approximately 45% of the node showed areas diagnostic of small lymphocytic lymphoma (SLL) with atypical small lymphocytes and scattered prolymphocytes. Immunohistochemistry demonstrated a positive staining for CD20 and CD23, but not for CD5 (Figure 1). Another 50% of the node showed a diffuse large cell lymphoma with anaplastic morphology. This component was positive for CD30, CD45, TIA-1, and UCHL-1 and was focally positive for epithelial membrane antigen (EMA). No staining was observed for CD20, CD3, CD15, ALK-1, and TARC. A small area of the node showed Hodgkin-like morphology with a mixture of R-S cells, typical small lymphocytes, and eosinophils. The R-S cells in the HL area stained positive for TIA-1, CD30, CD15, and TARC (Figure 1). The small lymphocytes surrounding the R-S cells stained for CD3. No staining was detected in the R-S cells for ALK-1, EMA, CD20, CD45, and UCHL-1. Based on the morphology and immunophenotype, this HL can be classified as a mixed cellularity classical HL. EBV in situ hybridization showed no positive signal in any of the lymphoma areas.

IgH gene rearrangements were amplified in 2 parallel experiments. The frozen tissue blocks used for these experiments consisted mainly of the CLL and ALCL components. The HL component in this material was limited to a very small area and allowed the analysis of only 10 cells in a duplicate experiment. The Hodgkin component was present and more pronounced in the paraffin tissue block, but this material could not be amplified successfully. The FRII and FRIII PCR revealed discrete bands of the same size for the total tissue and also for the CLL and ALCL components. The VDJ-PCR revealed a PCR product with the VH3 family–specific primer for the whole tissue section and for both tumor components separately. After subcloning, the inserts of 10 independent clones originating from both lymphoma areas were sequenced. Comparison of these sequences to the germ line sequence using the FASTA program (http://ncbi.nih.nlm.com/) revealed that 6 CLL (nos. 1-6) and 5 ALCL clones (nos. 11-15) corresponded to VH3-30, whereas the remaining 4 CLL (nos. 7-10) and 5 ALCL clones (nos. 16-20) corresponded to VH3-23 (Figure 2). For the HL component, only one experiment revealed a PCR product. Cloning and sequence analysis of the resulting PCR product revealed 4 clones (nos. 21-24) corresponding to VH3-30 with somatic mutations identical to the CLL and ALCL components and 2 clones (nos. 25, 26) corresponding to VH3-23 with a sequence homologous to the CLL and ALCL components. The somatic mutations (2.5%) observed in the VH3-30 allele were identical for all 3 components; no functional open reading frame (ORF) could be identified within this sequence. A low level of scattered mutations could be identified in the different clones, but these mutations might be caused by replication errors of the Taq-polymerase. The second allele, with a mutation frequency of more than 10%, was identical for the CLL and ALCL components. Again, low frequencies of scattered mutations were detected in the different clones. A further analysis of this sequence revealed a functional ORF. The HL component shared most of the somatic mutations with the CLL and ALCL component. However, the 3’ part of the sequence of these 2 clones showed a much higher degree of identity to the 3′ sequence of the VH3-23 allele (Figure 2). Because these 2 sequences are derived from a single PCR using
only 10 microdissected R-S cells, it cannot be excluded that this presumed crossing-over event represents a PCR artifact.

Discussion

Although the morphology and immunophenotype of the CLL, ALC, and HL components suggested different lymphomas, our analyses clearly demonstrate a common precursor cell for all 3 components. The previous diagnosis of CLL in this patient suggests that additional changes in the CLL tumor cells have led to the development of the ALC and HL components. The CLL component was CD5+ and contained a rearranged IgH gene with the presence of a high percentage of somatic mutations, suggesting a postterminal center B-cell origin. Presence of somatically mutated IgH genes is a frequent finding for CD5-CD23+ CLL cases. In general, most CLL cases are CD5+ and frequently express IgH genes in germ line configuration. The CLL component of 2 previously reported CLL/HL composite lymphomas with a common precursor cell were CD5+, but also contained mutated IgH genes. The ALC component has an immunophenotype, that is, CD30+ CD45RO+ TIA-1+ CD20- ALK+, suggesting a T/0 origin. The results of the IgH gene analyses, however, clearly demonstrate the presence of a monoclonal IgH gene rearrangement in the ALC component. Analysis for T-cell receptor rearrangement in the CLL and ALC components revealed no PCR products, whereas polyclonal- or monoclonal-positive control samples did yield PCR products. Additional analysis on an automated sequencer indeed revealed monoclonal or polyclonal patterns in the control samples and only very low peaks, resembling the polyclonal pattern of the controls, for the CLL and ALC components (results not shown). The HL component contained the same clonal IgH rearrangements as the ALC and CLL components, sharing most somatic mutations. There was no indication for the presence of ongoing mutations, indicating that the hypermutation process was no longer active. No EBV was found in any of the components of the lymphoma, indicating an oncogenic pathway independent of EBV.

Several studies report the presence of EBV at high frequencies in the HL components, whereas no EBV was detected in the CLL/SLL components. Rubin et al showed a single immunoglobulin rearrangement upon a Southern blot analysis in 2 EBV+ cases. Although this might suggest a clonal relation, no convincing evidence has been reported to prove a clonal relation between the HL and CLL component. Three studies reported that R-S cells in rare cases of B-CLL might share the same IgH gene rearrangement with the CLL cells. Kanzler et al reported 2 cases with EBV+ R-S cells that were derived from a different B-cell clone than the CLL cells, whereas the R-S cells in the EBV+ case were derived from the same clone as the CLL cells. Ohno et al showed a clonal relationship between R-S cells and CLL cells in 2 cases; the presence of EBV was not investigated. Küppers et al detected a clonal relation between CLL and EBV+ HL in a fourth case. In the present case the ALC cells and the R-S cells were clonally related to the CLL cells and were also EBV negative. Together, these data suggest that a clonal relation might be restricted to EBV-negative cases, whereas EBV-positive Hodgkin cells develop as independent malignancies as a consequence of the immunodeficiencies often seen in CLL patients.

A surprising and not previously reported finding in this case is the apparent T- or 0-cell immunophenotype (see above) of the ALC component despite the presence of clonal Ig gene rearrangements. EMA and TIA-1 can occasionally be found in large-cell B-cell lymphomas and in R-S cells. CD45 is a transmembrane protein tyrosine phosphatase involved in T-cell differentiation and activation and also in B-cell activation. The presence of CD45RO is generally considered a marker for T cells but can also be detected on B cells differentiating toward immunoblasts and in approximately 5% of B-cell lymphomas, preferentially in association with EMA. Our case demonstrates that immunophenotype cannot be used as convincing evidence of T- or 0-type ALC. In the absence of staining for CD3, the true genotype of so-called T- or 0-cell ALC can only be determined by Ig and TCR gene rearrangement analysis.

The immunophenotype of the R-S cells was largely identical to that of the ALC, including the strong staining for TIA-1. However, the R-S cells also expressed CD15 and TARC. CD15 is strongly associated with R-S cells of classical HL, but the significance of this molecule is not known. TARC is a CC chemokine that is aberrantly expressed by R-S cells of classical HL. The presence of TARC, which binds CCR4, TH2-type lymphocytes, in R-S cells and its absence in the ALC area might explain the presence of infiltrating lymphocytes in the Hodgkin area. The findings indicate transformation of the CLL cells to an ALC and HL component. A schematic representation of the cumulative changes detected in transformation from CLL to ALC and to HL components is given in Figure 3.

Acknowledgments

The authors thank R. Küppers (Cologne, Germany) and C. J. van Noesel (Amsterdam, The Netherlands) for helpful discussions about the sequence analysis of the immunoglobulin heavy chain gene.

References

5. Tsang WY, Chan JK, Ng CS. Epstein-Barr virus


Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma

Anke van den Berg, Ewerton Maggio, Renata Rust, Klaas Kooistra, Arjan Diepstra and Sibrand Poppema

Updated information and services can be found at:
http://www.bloodjournal.org/content/100/4/1425.full.html

Articles on similar topics can be found in the following Blood collections

Neoplasia (4182 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml